Reported about 12 hours ago
Leerink has downgraded Eli Lilly and Company (NYSE:LLY) from Outperform to Market Perform with a target price of $715, following a significant 38% revenue increase to $15.56 billion in Q2 2025, largely due to Zepbound and Mounjaro sales. Despite raising its full-year revenue guidance and EPS expectations, analysts suggest that other stocks, particularly in AI, may offer better investment potential.
Source: YAHOO